Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators will study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 70
Healthy Volunteers: f
View:
• Suspected or diagnosed OSA
• Recent drug induced sleep endoscopy results available (performed as part of routine clinical care).
Locations
United States
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Contact Information
Primary
Scott A Sands, PhD
sasands@bwh.harvard.edu
617-278-0911
Backup
Laura K Gell, PhD
lgell@bwh.harvard.edu
617-525-9086
Time Frame
Start Date: 2022-05-05
Estimated Completion Date: 2024-12
Participants
Target number of participants: 22
Treatments
Experimental: AtoOxy Predicted Responders
Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
Experimental: AtoOxy Predicted Nonresponders
Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
Related Therapeutic Areas
Sponsors
Leads: Brigham and Women's Hospital